

October 28, 2020

To,

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001

Dear Sirs,

Sub: Presentation on Quarterly Results for the quarter / half year ended 30-09-2020.

--o--

We are forwarding a copy of Presentation on Quarterly Results of our company for the quarter / half year ended 30-09-2020.

Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised.

Yours Faithfully,

For Thyrocare Technologies Limited,



Ramjee Dorai
Company Secretary and Compliance Officer



Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India ☎ 022- 3090 0000 / 4125 2525

✉ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)



Thyrocare Technologies Limited

Presentation – Q22021

Disclaimer

This presentation is for information purposes only and it contains general background information about the Company's activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, information or events, or otherwise. This Presentation comprises information given in summary form and does not purport to be complete. This Presentation should not be considered as a recommendation to any investor to purchase the equity shares of the Company. This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future financial condition and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. The past performance is not indicative of future results.

This document has not been and will not be reviewed or approved by the statutory auditors or a regulatory authority in India or by any stock exchange in India.

Key Highlights

Revenue from operations

Standalone Quarterly revenue increased by 38% YoY and 173% QoQ

Consolidated Quarterly revenue increased by 32% YoY and 172% QoQ

- Q2 Pathology Revenue of Rs. 148.54 Crore, consists of Covid RTPCR Revenue of Rs. 47.7 Crore.
- Pathology Revenue (excluding Covid RTPCR) in Q2, revived to the extent of 94%, with growth of 13% in September.
- Q2 Radiology Revenue of Rs. 4.71 Crore, with operations at selected centres commenced in August.
- Radiology revenue revived to the extent of 55% YOY, in Q2.

EBITDA

Standalone EBITDA margin (*adjusted*) 41.6%

Consolidated EBITDA margin (*adjusted*) 40.4%

Standalone EBITDA of Rs. 61.7 Crore, *adjusted for non operating expenses*, grew by about 4.8 times QoQ and about 21% YoY.

- Consolidated EBITDA of Rs. 61.9 Crore, *adjusted for non operating expenses*, grew by more than 5 times QoQ and by about 18% YoY.

Volumes

Samples processed in Q2 – 4.6 million (5.18 million Q2-2019)

Scans performed in Q2 – 3277 (Q2-2019 - 6537)

- Covid RTPCR tests reported in Q2 – 2,76,422.
- Covid Antibody tests reported in Q2 – 3,23,055.
- Pathology Volumes (excluding Covid RTPCR) in Q2, revived to the extent of 83%.
- Q2 Covid RTPCR volumes grew by 227% QoQ and non covid by 144%.

Financial Performance - Thyrocare

Thyrocare Technologies Limited									
Statement of Unaudited Standalone Financial Results					(Rs. in crore, except per share data)				
Particulars	Quarter ended				Half Year ended				
	30.09.2020	%	30.09.2019	%	30.09.2020	%	30.09.2019	%	
Revenue from operations	148.54		107.89		202.94		208.39		
Cost of Materials consumed/ sales	50.14	34%	29.99	28%	75.76	37%	59.51	29%	
Gross margins	98.40	66%	77.90	72%	127.18	63%	148.88	71%	
Operating expenses :									
Employee benefits expense	12.76	9%	10.59	10%	21.75	11%	21.25	10%	
Other expenses	23.92	16%	16.39	15%	33.06	16%	32.63	16%	
Normalised EBITDA	61.72	42%	50.92	47%	72.37	36%	95.00	46%	
Finance cost	0.22	0.1%	0.47	0.4%	0.42	0.2%	0.79	0.4%	
Depreciation and amortisation expense	5.24	4%	5.18	5%	9.72	5%	9.27	4%	
Operating profit	56.26	38%	45.27	42%	62.23	31%	84.94	41%	
Other income, net (<i>Non-operating</i>)	5.36		3.36		6.85		6.71		
Exceptional items and others (<i>Non-operating</i>)	(0.04)		(0.20)		(1.18)		(0.26)		
Profit before taxes	61.58		48.43		67.90		91.39		
Income tax and deferred tax	(15.81)		(11.00)		(17.71)		(23.86)		
Profit after taxes	45.77	31%	37.43	35%	50.19	25%	67.53	32%	
Earnings per equity share									
Basic	8.67		7.09		9.51		12.79		
Diluted	8.64		7.07		9.49		12.76		

Operational Performance - Thyrocare


Revenue from operations (in crore)
Monthwise




Revenue from operations
(Rs. in crore)



Samples reported (in millions)
Monthwise



Samples processed
(in millions)




Financial Performance - Nuclear

Nuclear Healthcare Limited									
Statement of Unaudited Standalone Financial Results					(Rs. in crore, except per share data)				
Particulars	Quarter ended				Half Year ended				
	30.09.2020	%	30.09.2019	%	30.09.2020	%	30.09.2019	%	
Revenue from operations	4.71		8.61		6.57		18.08		
Cost of Materials consumed/ sales	0.71	15%	1.23	14%	1.05	16%	2.57	14%	
Gross margins	4.00	85%	7.38	86%	5.52	84%	15.51	86%	
Operating expenses :									
Employee benefits expense	0.35	7%	0.83	10%	0.58	9%	1.70	9%	
Other expenses	3.78		5.31		6.16		11.15		
Normalised EBITDA	(0.13)		1.25		(1.22)		2.66		
Finance cost	0.44		1.02		0.87		2.06		
Depreciation and amortisation expense	2.51		3.10		5.01		6.43		
Operating profit	(3.08)		(2.88)		(7.09)		(5.82)		
Other income, net (<i>Non-operating</i>)	0.14		0.22		0.19		0.36		
Exceptional items and others (<i>Non-operating</i>)	-		-		-		-		
Profit before taxes	(2.94)		(2.66)		(6.91)		(5.47)		
Income tax and deferred tax	-		-		-		-		
Profit after taxes	(2.94)		(2.66)		(6.91)		(5.47)		
Earnings per equity share									
Basic	(2.65)		(2.39)		(6.22)		(4.92)		
Diluted	(2.65)		(2.39)		(6.22)		(4.92)		


Operational Performance - Nuclear

**Revenue from operations
(Rs. in crore)**



Centre Revenue (in crore)	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Total
Navi Mumbai	0.09	0.13	0.13	0.18	0.25	0.25	1.02
Delhi	0.00	0.00	0.01	0.12	0.12	0.13	0.38
Hyderabad	0.01	0.00	0.02	0.15	0.20	0.31	0.69
Prabhadevi	0.10	0.13	0.23	0.17	0.24	0.29	1.16
Aurangabad	0.06	0.07	0.14	0.13	0.12	0.17	0.68
Jaipur	0.00	0.08	0.15	0.20	0.19	0.23	0.85
Nashik	0.09	0.13	0.21	0.17	0.16	0.19	0.94
Bangalore	0.00	0.00	0.00	0.00	0.01	0.03	0.04
Total	0.35	0.53	0.89	1.12	1.28	1.61	5.78

Scans performed



Centre Scans	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Total
Navi Mumbai	87	112	107	156	223	226	911
Delhi	4	-	11	108	111	127	361
Hyderabad	5	-	18	136	177	285	621
Prabhadevi	94	112	204	153	211	263	1,037
Aurangabad	40	42	90	86	81	115	454
Jaipur	-	57	108	144	137	153	599
Nashik	61	87	145	117	108	130	648
Bangalore	-	-	-	-	5	25	30
Total	291	410	683	900	1,053	1,324	4,661

Consolidated Financial Performance - Thyrocare

Thyrocare Technologies Limited [Consolidated]					(Rs. in crore, except per share data)				
Statement of Unaudited Consolidated Financial Results									
Particulars	Quarter ended				Half Year ended				
	30.09.2020	%	30.09.2019	%	30.09.2020	%	30.09.2019	%	
Revenue from operations	153.25		116.24		209.52		225.97		
Cost of Materials consumed/ sales	50.85	33%	31.21	27%	76.81	37%	62.07	27%	
Gross margins	102.40	67%	85.03	73%	132.71	63%	163.90	73%	
Operating expenses :									
Employee benefits expense	13.10	9%	11.42	10%	22.32	11%	22.95	10%	
Other expenses	27.35	18%	21.25	18%	38.85	19%	42.92	19%	
Normalised EBITDA	61.95	40%	52.36	45%	71.54	34%	98.03	43%	
Finance cost	0.34	0.2%	0.61	0.5%	0.66	0.3%	1.08	0.5%	
Depreciation and amortisation expense	7.64	5%	8.23	7%	14.61	7%	15.58	7%	
Operating profit	53.97	35%	43.52	37%	56.27	27%	81.37	36%	
Other income, net (<i>Non-operating</i>)	4.98		2.46		6.21		4.82		
Exceptional items and others (<i>Non-operating</i>)	(0.10)		0.07		(1.50)		0.19		
Profit before taxes	58.85		46.05		60.98		86.38		
Income tax and deferred tax	(15.81)		(11.00)		(17.71)		(23.86)		
Profit after taxes	43.05		35.05		43.28		62.52		
Earnings per equity share									
Basic	8.15		6.73		8.19		11.84		
Diluted	8.13		6.71		8.17		11.81		

YTD Performance - Thyrocare

Revenue from operations
(Rs. in crore)



YTD Updates

- ✓ Total Revenue from pathology business (including Covid RTPCR) – Rs. 202.94 Crore (Previous Year – Rs. 208.39 Crore).
- ✓ Total Revenue from Covid RTPCR – Rs. 71.01 Crore (35.1% of Total revenue from pathology business)
- ✓ Total non covid samples processed and reported – 6.09 million (Previous Year – 10.18 million)
- ✓ Total Covid RTPCR samples processed and reported – 0.36 million Total Covid antibody samples process and reported – 0.32 million.
- ✓ Total Revenue from radiology business (including FDG sales) – Rs. 6.57 Crore (Previous Year – Rs. 18.08 Crore).
- ✓ Total PETCT scans performed – 4661 (Previous Year – 14131)

THANK YOU
